CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models

BACKGROUND The majority of prostate cancer (Pca) patient morbidity can be attributed to bone metastatic events, which poses a significant clinical obstacle. Therefore, a better understanding of this phenomenon is imperative and might help to develop novel therapeutic strategies. Stromal cell‐derived...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Prostate 2015-09, Vol.75 (12), p.1227-1246
Hauptverfasser:	Gravina, Giovanni Luca, Mancini, Andrea, Muzi, Paola, Ventura, Luca, Biordi, Leda, Ricevuto, Enrico, Pompili, Simona, Mattei, Claudia, Di Cesare, Ernesto, Jannini, Emmanuele A., Festuccia, Claudio
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - pharmacology Antiviral Agents - pharmacology Blotting, Western bone metastases Bone Neoplasms - secondary Cell Adhesion Cell Movement Chemokine CXCL12 - metabolism Coculture Techniques CXCR4 Disease Models, Animal Enzyme-Linked Immunosorbent Assay Heterocyclic Compounds - pharmacology Heterografts Humans Immunohistochemistry Lymph Nodes - pathology Lymphatic Metastasis Male Mice Mice, Nude Peptides - pharmacology Plerixafor prostate cancer Prostatic Neoplasms - metabolism Prostatic Neoplasms - pathology Receptors, CXCR4 - antagonists & inhibitors Receptors, CXCR4 - metabolism Tomography, X-Ray Computed Tumor Cells, Cultured Vascular Endothelial Growth Factor A - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!